Upgrade to SI Premium - Free Trial

Tenet Healthcare (THC) Reports Q1 EPS of $0.57, Beats on Revenues; Boosts FY18 EPS/EBITDA Outlook

April 30, 2018 4:21 PM

Tenet Healthcare (NYSE: THC) reported Q1 EPS of $0.57, versus ($0.03) reported last year. Revenue for the quarter came in at $4.7 billion versus the consensus estimate of $4.59 billion.

“The actions we have taken to be a more efficient, agile and decisive organization have resulted in stronger financial performance,” said Ronald A. Rittenmeyer, executive chairman and CEO. “We are continuing our focus on improving quality, growth and financial results and will be exploring additional opportunities to enhance margins and shareholder returns.”

Outlook

The Company’s revised Outlook for 2018 includes:

The Company raised the midpoint of its previous 2018 Adjusted EBITDA Outlook range by $50 million to reflect higher expectations for Conifer, primarily as a result of the business achieving improvements in its cost structure on a faster pace than previously anticipated.

The Outlook for 2018 assumes equity in earnings of unconsolidated affiliates of $160 million to $170 million, net income attributable to noncontrolling interests of $410 million to $430 million and an average diluted share count of 103 million. The Outlook for net income attributable to noncontrolling interests reflects a reduction in noncontrolling interest expense as a result of Tenet increasing its ownership in USPI from 80 percent to 95 percent, effective April 26, 2018, substantially offset by increased noncontrolling interest expense at Conifer resulting from our increased expectations for Conifer’s net income this year.

The Company’s Outlook for the second quarter of 2018 includes:

GUIDANCE:

Tenet Healthcare sees FY2018 EPS of $1.36-$1.70, versus the consensus of $0.92. Tenet Healthcare sees FY2018 revenue of $17.9-18.3 billion, versus the consensus of $18.09 billion.

For earnings history and earnings-related data on Tenet Healthcare (THC) click here.

Categories

Earnings Guidance Hot Guidance

Next Articles